Ankur Parikh, DO
Hematology & Oncology · Philadelphia, PANPI 1245499144
Payments from drug & device makers
Across 138 payments — averaging $2842.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Foundation Medicine, Inc.$324K
- Merck$64K
- Bayer$3K
- Tempus AI, Inc$249
- Boston Scientific$144
- Regeneron Healthcare Solutions, Inc.$112
- plus $342 from 6 others
Across 5 payments — averaging $962.02 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$5K
- Eli Lilly$264
What the payments were for
- Consulting fees$291,36289%
- Speaking & faculty fees$33,34510%
- Travel & lodging$2,5411%
- Food & beverage$1,7371%
- Education$680%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Foundation Medicine, Inc. | 77 | $324,329 |
| Merck | 44 | $64,081 |
| Bayer | 3 | $3,060 |
| Tempus AI, Inc | 2 | $249 |
| Boston Scientific | 1 | $144 |
| Regeneron Healthcare Solutions, Inc. | 3 | $112 |
| Astellas Pharma US Inc | 1 | $106 |
| AstraZeneca | 1 | $68 |
| Alimera Sciences, Inc. | 1 | $66 |
| E.r. Squibb & Sons, L.L.C. | 3 | $61 |
| Array Biopharma Inc | 1 | $22 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FOUNDATIONONE CDX$324,220
- FOUNDATIONFOCUS$120,158
- FOUNDATIONONE HEME$120,158
- FOUNDATIONONE$120,158
- FOUNDATIONONE LIQUID$114,386
- FOUNDATIONACT$5,772
- Vitrakvi$2,300
- Stivarga$760
- MK-7339$473
- XT CDX$249
- TheraSphere Y90 Glass Microspheres 10 GBq$144
- XOSPATA$106
How this compares
$392,317 in reported general payments places this provider in the 85th percentile of 682 hematology & oncology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VerzenioAbemaciclib | 13 | $194,678 |
| Prochlorperazine Maleate | 61 | $1,074 |
| Dexamethasone | 14 | $595 |
| Ondansetron Hcl | 66 | $297 |
| Pantoprazole Sodium | 13 | $261 |
| Sodium Chloride0.9 % Sodium Chloride | 17 | $154 |
| LoperamideLoperamide Hcl | 23 | $133 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Philadelphia
- Stephen BagleyPhiladelphia$13.1M
- Stephen SchusterPhiladelphia$9.5M
- Pooja GhataliaPhiladelphia$8.3M
- Corey LangerPhiladelphia$7.7M
- Alfred GarfallPhiladelphia$7.6M
- Charu AggarwalPhiladelphia$7M
- Marcela MausPhiladelphia$4.4M
- Catherine LaiPhiladelphia$3.8M
- James StevensonPhiladelphia$3.4M
- Tara MitchellPhiladelphia$3.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.